Trishna Goswami, M.D.

Trishna has served as our Chief Medical Officer since November 2021. She brings over a decade of experience in clinical drug development including experience with antibody drug conjugates and immunotherapy. Dr Goswami most recently served as Vice President, Clinical Development at Gilead Sciences, Inc., which she joined through its acquisition of Immunomedics in 2020.

At Immunomedics she led a team that secured accelerated approval of Trodelvy® in bladder cancer and contributed to securing full FDA approval in triple-negative breast cancer. Prior to Gilead/Immunomedics, she served as a Senior Medical Director at Stemline Therapeutics, Inc. where she oversaw the development of multiple hematologic assets and helped secure approval of ELZONRIS® (tagraxofusp). Dr. Goswami was previously at MedImmune, then AstraZeneca/MedImmune post-acquisition, where she managed biologics development for hematologic indications, launching the first phase 3 trial in an oncology indication at MedImmune. At AstraZeneca, Dr. Goswami also participated in the development of IMFINZI® (durvalumab) and tremelimumab. Before her career in industry, Dr. Goswami served as Assistant Professor, Department of Medicine, Division of Hematology/Oncology at the University of Maryland. She is an author of multiple publications during her tenure in academia and industry.

Dr. Goswami earned her M.D. from Drexel University College of Medicine, completed her postgraduate training in internal medicine and hematology/oncology at Georgetown University Hospital and completed her MBA from Smith School of Business at the University of Maryland.